Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge

T. J. Lampidis, D. Kolonias, T. Podona, M. Israel, A. R. Safa, Leonard Lothstein, N. Savaraj, H. Tapiero, W. Priebe

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

From a number of studies it has been suggested that positive charge and degree of lipophilicity dictate, or at least influence, whether anthracyclines are recognized by the apparently clinical important mechanism of tumor cell resistance, i.e., P-gp-mediated multidrug resistance. Using a selected series of analogs in which lipophilicity and or positive charge are altered we find the following: (1) Positively-charged anthracyclines as compared to their neutral counterparts are better recognized by MDR+ cells. (2) With increasing lipophilicity charge becomes less important for MDR recognition. (3) In MDR+ cells with a resistance index to Adriamycin (ADR) of 4534, as compared to an MDR- parental line, almost all of the resistance is circumvented (resistance index = 3) with an anthracycline which does not contain a protonatable nitrogen and is highly lipophilic (partition coefficient, log p = > 1.99). (4) As lipophilicity is increased to log p > 1.99 and nuclear binding is decreased, anthracycline localization switches from nuclear to cytoplasmic which most likely indicates a different cytotoxic target and mechanism of action. (5) Cytoplasmically localized anthracyclines appear to distribute also in mitochondria which suggests these organelles as possible new anthracycline targets. In contrast, ADR shows no mitochondrial localization. (6) Photoaffinity analysis suggests that the highly lipophilic analogs, regardless of charge, interfere with NASV-Vp binding to P-gp. This is consistent with the idea that highly lipophilic anthracyclines act as modulators of MDR which may contribute to their mechanism of overcoming this form of resistance. The possible clinical significance of these data is that highly lipophilic anthracyclines are shown to circumvent MDR which most likely reflects their ability to localize in the cytoplasm and affect targets other than nuclear DNA, i.e., mitochondria, and to act as self modulators of MDR. Thus, a new approach to circumventing MDR and other mechanisms of resistance which involve nuclear targets is the use of active anthracyclines which are highly lipophilic and localize in the cytoplasm/mitochondria.

Original languageEnglish (US)
Pages (from-to)2679-2685
Number of pages7
JournalBiochemistry
Volume36
Issue number9
DOIs
StatePublished - Mar 4 1997

Fingerprint

Anthracyclines
Mitochondria
Doxorubicin
Modulators
Cytoplasm
Multiple Drug Resistance
Organelles
Tumors
Nitrogen
Cells
Switches
DNA

All Science Journal Classification (ASJC) codes

  • Biochemistry

Cite this

Lampidis, T. J., Kolonias, D., Podona, T., Israel, M., Safa, A. R., Lothstein, L., ... Priebe, W. (1997). Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry, 36(9), 2679-2685. https://doi.org/10.1021/bi9614489

Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. / Lampidis, T. J.; Kolonias, D.; Podona, T.; Israel, M.; Safa, A. R.; Lothstein, Leonard; Savaraj, N.; Tapiero, H.; Priebe, W.

In: Biochemistry, Vol. 36, No. 9, 04.03.1997, p. 2679-2685.

Research output: Contribution to journalArticle

Lampidis, TJ, Kolonias, D, Podona, T, Israel, M, Safa, AR, Lothstein, L, Savaraj, N, Tapiero, H & Priebe, W 1997, 'Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge', Biochemistry, vol. 36, no. 9, pp. 2679-2685. https://doi.org/10.1021/bi9614489
Lampidis, T. J. ; Kolonias, D. ; Podona, T. ; Israel, M. ; Safa, A. R. ; Lothstein, Leonard ; Savaraj, N. ; Tapiero, H. ; Priebe, W. / Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. In: Biochemistry. 1997 ; Vol. 36, No. 9. pp. 2679-2685.
@article{0a08600bdc6941dfb8b7606ae7f7986b,
title = "Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge",
abstract = "From a number of studies it has been suggested that positive charge and degree of lipophilicity dictate, or at least influence, whether anthracyclines are recognized by the apparently clinical important mechanism of tumor cell resistance, i.e., P-gp-mediated multidrug resistance. Using a selected series of analogs in which lipophilicity and or positive charge are altered we find the following: (1) Positively-charged anthracyclines as compared to their neutral counterparts are better recognized by MDR+ cells. (2) With increasing lipophilicity charge becomes less important for MDR recognition. (3) In MDR+ cells with a resistance index to Adriamycin (ADR) of 4534, as compared to an MDR- parental line, almost all of the resistance is circumvented (resistance index = 3) with an anthracycline which does not contain a protonatable nitrogen and is highly lipophilic (partition coefficient, log p = > 1.99). (4) As lipophilicity is increased to log p > 1.99 and nuclear binding is decreased, anthracycline localization switches from nuclear to cytoplasmic which most likely indicates a different cytotoxic target and mechanism of action. (5) Cytoplasmically localized anthracyclines appear to distribute also in mitochondria which suggests these organelles as possible new anthracycline targets. In contrast, ADR shows no mitochondrial localization. (6) Photoaffinity analysis suggests that the highly lipophilic analogs, regardless of charge, interfere with NASV-Vp binding to P-gp. This is consistent with the idea that highly lipophilic anthracyclines act as modulators of MDR which may contribute to their mechanism of overcoming this form of resistance. The possible clinical significance of these data is that highly lipophilic anthracyclines are shown to circumvent MDR which most likely reflects their ability to localize in the cytoplasm and affect targets other than nuclear DNA, i.e., mitochondria, and to act as self modulators of MDR. Thus, a new approach to circumventing MDR and other mechanisms of resistance which involve nuclear targets is the use of active anthracyclines which are highly lipophilic and localize in the cytoplasm/mitochondria.",
author = "Lampidis, {T. J.} and D. Kolonias and T. Podona and M. Israel and Safa, {A. R.} and Leonard Lothstein and N. Savaraj and H. Tapiero and W. Priebe",
year = "1997",
month = "3",
day = "4",
doi = "10.1021/bi9614489",
language = "English (US)",
volume = "36",
pages = "2679--2685",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge

AU - Lampidis, T. J.

AU - Kolonias, D.

AU - Podona, T.

AU - Israel, M.

AU - Safa, A. R.

AU - Lothstein, Leonard

AU - Savaraj, N.

AU - Tapiero, H.

AU - Priebe, W.

PY - 1997/3/4

Y1 - 1997/3/4

N2 - From a number of studies it has been suggested that positive charge and degree of lipophilicity dictate, or at least influence, whether anthracyclines are recognized by the apparently clinical important mechanism of tumor cell resistance, i.e., P-gp-mediated multidrug resistance. Using a selected series of analogs in which lipophilicity and or positive charge are altered we find the following: (1) Positively-charged anthracyclines as compared to their neutral counterparts are better recognized by MDR+ cells. (2) With increasing lipophilicity charge becomes less important for MDR recognition. (3) In MDR+ cells with a resistance index to Adriamycin (ADR) of 4534, as compared to an MDR- parental line, almost all of the resistance is circumvented (resistance index = 3) with an anthracycline which does not contain a protonatable nitrogen and is highly lipophilic (partition coefficient, log p = > 1.99). (4) As lipophilicity is increased to log p > 1.99 and nuclear binding is decreased, anthracycline localization switches from nuclear to cytoplasmic which most likely indicates a different cytotoxic target and mechanism of action. (5) Cytoplasmically localized anthracyclines appear to distribute also in mitochondria which suggests these organelles as possible new anthracycline targets. In contrast, ADR shows no mitochondrial localization. (6) Photoaffinity analysis suggests that the highly lipophilic analogs, regardless of charge, interfere with NASV-Vp binding to P-gp. This is consistent with the idea that highly lipophilic anthracyclines act as modulators of MDR which may contribute to their mechanism of overcoming this form of resistance. The possible clinical significance of these data is that highly lipophilic anthracyclines are shown to circumvent MDR which most likely reflects their ability to localize in the cytoplasm and affect targets other than nuclear DNA, i.e., mitochondria, and to act as self modulators of MDR. Thus, a new approach to circumventing MDR and other mechanisms of resistance which involve nuclear targets is the use of active anthracyclines which are highly lipophilic and localize in the cytoplasm/mitochondria.

AB - From a number of studies it has been suggested that positive charge and degree of lipophilicity dictate, or at least influence, whether anthracyclines are recognized by the apparently clinical important mechanism of tumor cell resistance, i.e., P-gp-mediated multidrug resistance. Using a selected series of analogs in which lipophilicity and or positive charge are altered we find the following: (1) Positively-charged anthracyclines as compared to their neutral counterparts are better recognized by MDR+ cells. (2) With increasing lipophilicity charge becomes less important for MDR recognition. (3) In MDR+ cells with a resistance index to Adriamycin (ADR) of 4534, as compared to an MDR- parental line, almost all of the resistance is circumvented (resistance index = 3) with an anthracycline which does not contain a protonatable nitrogen and is highly lipophilic (partition coefficient, log p = > 1.99). (4) As lipophilicity is increased to log p > 1.99 and nuclear binding is decreased, anthracycline localization switches from nuclear to cytoplasmic which most likely indicates a different cytotoxic target and mechanism of action. (5) Cytoplasmically localized anthracyclines appear to distribute also in mitochondria which suggests these organelles as possible new anthracycline targets. In contrast, ADR shows no mitochondrial localization. (6) Photoaffinity analysis suggests that the highly lipophilic analogs, regardless of charge, interfere with NASV-Vp binding to P-gp. This is consistent with the idea that highly lipophilic anthracyclines act as modulators of MDR which may contribute to their mechanism of overcoming this form of resistance. The possible clinical significance of these data is that highly lipophilic anthracyclines are shown to circumvent MDR which most likely reflects their ability to localize in the cytoplasm and affect targets other than nuclear DNA, i.e., mitochondria, and to act as self modulators of MDR. Thus, a new approach to circumventing MDR and other mechanisms of resistance which involve nuclear targets is the use of active anthracyclines which are highly lipophilic and localize in the cytoplasm/mitochondria.

UR - http://www.scopus.com/inward/record.url?scp=0031017789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031017789&partnerID=8YFLogxK

U2 - 10.1021/bi9614489

DO - 10.1021/bi9614489

M3 - Article

VL - 36

SP - 2679

EP - 2685

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 9

ER -